JP2022511497A5 - - Google Patents

Info

Publication number
JP2022511497A5
JP2022511497A5 JP2021531817A JP2021531817A JP2022511497A5 JP 2022511497 A5 JP2022511497 A5 JP 2022511497A5 JP 2021531817 A JP2021531817 A JP 2021531817A JP 2021531817 A JP2021531817 A JP 2021531817A JP 2022511497 A5 JP2022511497 A5 JP 2022511497A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
elastrant
estrogen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511497A (ja
JP7497353B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064980 external-priority patent/WO2020118202A1/en
Publication of JP2022511497A publication Critical patent/JP2022511497A/ja
Publication of JP2022511497A5 publication Critical patent/JP2022511497A5/ja
Priority to JP2024086821A priority Critical patent/JP2024101017A/ja
Application granted granted Critical
Publication of JP7497353B2 publication Critical patent/JP7497353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531817A 2018-12-06 2019-12-06 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法 Active JP7497353B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086821A JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
US62/776,338 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086821A Division JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Publications (3)

Publication Number Publication Date
JP2022511497A JP2022511497A (ja) 2022-01-31
JP2022511497A5 true JP2022511497A5 (https=) 2022-12-19
JP7497353B2 JP7497353B2 (ja) 2024-06-10

Family

ID=69158304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531817A Active JP7497353B2 (ja) 2018-12-06 2019-12-06 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
JP2024086821A Pending JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086821A Pending JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Country Status (17)

Country Link
US (2) US20220016052A1 (https=)
EP (1) EP3890835A1 (https=)
JP (2) JP7497353B2 (https=)
KR (1) KR20210100135A (https=)
AU (1) AU2019392908B2 (https=)
BR (1) BR112021010141A2 (https=)
CA (1) CA3121918A1 (https=)
EA (1) EA202191256A1 (https=)
IL (1) IL283655A (https=)
JO (1) JOP20210138B1 (https=)
MA (1) MA54393A (https=)
MX (1) MX2021006412A (https=)
MY (1) MY208702A (https=)
PH (1) PH12021551327A1 (https=)
SG (1) SG11202105915UA (https=)
UA (1) UA129588C2 (https=)
WO (1) WO2020118202A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3055185T3 (en) * 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법

Similar Documents

Publication Publication Date Title
JP2018518529A5 (https=)
RU2017140675A (ru) Способы лечения рака
JP2018514549A5 (https=)
JP2022511498A5 (https=)
EP4157465A2 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
WO2024211271A1 (en) Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
JP2022511497A5 (https=)
Guan et al. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis
RU2021116293A (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
RU2021116084A (ru) Способы лечения рака на моделях, имеющих мутации esr1
NZ737822B2 (en) Methods of treating cancer
Heidenreich et al. Targeted therapy in patients with metastatic male germ cell tumors
NZ737819B2 (en) Methods for treating cancer
US20240096469A1 (en) Methods of predicting responses to disease treatments
CN119497613A (zh) 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
WO2019174590A1 (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
ES2898072T3 (es) Métodos para tratar el cáncer de ovario
JP7608369B2 (ja) エストロゲン受容体アルファ阻害剤の経口剤形を用いて癌を治療する方法
Tamborero Noguera et al. Cancer bioMarkers database
JP2022541610A (ja) エストロゲン受容体調節化合物
JP7497353B2 (ja) Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
RU2844940C2 (ru) Способ лечения рака с помощью пероральной лекарственной формы ингибитора рецептора эстрогена альфа
RU2772432C2 (ru) Способы лечения рака яичника
WO2025162446A1 (zh) 一种egfr抑制剂的用途